Health Care & Life Sciences » Pharmaceuticals | Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
10,481.00
3,646.00
1,671.00
15,065.00
215.00
6,618
Cost of Goods Sold (COGS) incl. D&A
-
353.00
-
-
-
538
Gross Income
-
3,293.00
-
-
-
6,080
SG&A Expense
11,265.00
6,768.00
8,072.00
10,345.00
14,300.00
14,344
EBIT
891.00
3,475.00
6,759.00
4,343.00
14,502.00
8,264
Unusual Expense
12,637.00
1,083.00
4,512.00
825.00
619.00
134
Non Operating Income/Expense
467.00
11.00
8.00
70.00
55.00
6
Interest Expense
1,568.00
-
-
-
369.00
887
Pretax Income
9,711.00
2,403.00
11,279.00
5,135.00
14,307.00
9,023
Consolidated Net Income
9,711.00
2,403.00
11,279.00
5,135.00
14,307.00
9,023
Net Income
9,711.00
2,403.00
11,279.00
5,135.00
14,307.00
9,023
Net Income After Extraordinaries
9,711.00
2,403.00
11,279.00
5,135.00
14,307.00
9,023
Net Income Available to Common
9,711.00
2,403.00
11,279.00
5,135.00
14,307.00
9,308
EPS (Basic)
0.53
0.20
0.56
0.20
0.70
0.28
Basic Shares Outstanding
14,927.10
17,057.10
20,053.00
20,744.00
21,203.00
34,128
EPS (Diluted)
0.53
0.20
0.56
0.20
0.70
0.28
Diluted Shares Outstanding
15,028.90
17,060.40
20,053.00
21,459.00
21,228.00
34,128
EBITDA
784.00
3,122.00
6,401.00
4,720.00
14,085.00
7,884
Non-Operating Interest Income
-
-
-
37.00
-
-

About Titan Pharmaceuticals

View Profile
Address
400 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.titanpharm.com
Updated 07/08/2019
Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.